Highest-materiality recent filing
Kiora licenses South Korean rights for KIO-301 to CKD for $1M upfront plus milestones and royalties
$1M upfront payment from CKD for exclusive South Korean rights to KIO-301 for retinitis pigmentosa and other ophthalmic indications.
Kiora reports KIO-300 suppresses seizure activity in preclinical epilepsy model
KIO-300 significantly reduced epileptiform event frequency in hippocampal CA1 slices (p<0.0001).
Kiora shareholders approve 1.5M share increase to 2024 equity incentive plan
Stockholders approved amendment to 2024 Equity Incentive Plan, increasing authorized shares by 1,500,000.
Kiora Pharmaceuticals closes $5M private placement with Perceptive Advisors; warrants could add $19M
Closed private placement raising $5.0M upfront; potential $19M from warrant exercise.
Kiora Pharmaceuticals CDO Eric Daniels to resign April 17; successor search initiated
Eric J. Daniels resigns as Chief Development Officer effective April 17, 2026, to pursue other opportunities.
Kiora Pharmaceuticals reports FY2025 net loss of $10.8M; two Phase 2 trials underway
Net loss of $10.8M for 2025 vs net income of $3.6M in 2024 due to $16M upfront payment from Théa in prior year.
Kiora reports Q3 net income of $27K; cash runway into late 2027; two Phase 2 trials enrolling
Cash, equivalents and investments $19.4M; collaboration receivables $1.2M; tax receivables $1.5M.
Kiora Q2 net loss $2.2M; initiated two Phase 2 retinal trials, Senju deal up to $110M
Net loss of $2.2M in Q2 2025, flat YoY; cash and equivalents $20.7M, runway into late 2027.
Immediate $1.25M option payment; if exercised, mid-single-digit million upfront and up to $110M in development, regulatory, and commercial milestones.
Kiora Q1 net loss $2.2M; cash $24.1M into late 2027; initiates two Phase 2 trials
Net loss $2.2M vs net income $13.4M in Q1 2024 due to $16M upfront from Théa in prior year.
Kiora reports 2024 net income $3.6M; two Phase 2 retinal trials approved; cash runway into 2027
Year-end cash, equivalents, and short-term investments $26.8M; expected runway into 2027.
Kiora Q3 net loss $3.4M; cash $29M; advancing two Phase 2 retinal trials
Cash and equivalents $29.0M at Sept 30, plus $1.8M collaboration receivables; runway into 2027.
Kiora receives IND approval for Phase 2 trial of KIO-301 in retinitis pigmentosa
ABACUS-2 is a 36-patient, multi-center, double-masked, randomized, controlled Phase 2 trial.
Kiora reports Q2 net loss $2.2M, cash $27.8M; advancing two Phase 2 retinal trials
Q2 revenue $20K (grant); net R&D expense $0.9M after $1.1M TOI reimbursement credits.
Kiora appoints Walters-Hoffert to board, promotes Tosca to CFO, regains Nasdaq compliance
Lisa Walters-Hoffert appointed independent director and audit committee chair; Kenneth Gayron resigned.
1-for-9 reverse stock split filed June 6, 2024; effective at open of market on June 11, 2024.
Kiora Pharma Q1 net income $13.5M on $16M TOI revenue; $31.3M cash; KIO-301 Phase 2 on track
Ended Q1 with $31.3M cash plus $1.8M R&D tax credits; runway over 2 years.
Kiora shareholders approve reverse stock split and increase authorized shares to 150M
Reverse stock split of common stock approved at a ratio between 1-for-2 and 1-for-10; board will set exact ratio and timing.
Kiora reports 2023 net loss $12.5M; cash >$30M post partnership and placement
Net loss $12.5M in 2023 vs $13.6M in 2022; R&D expense $4.0M, G&A $4.7M.
Kiora Pharmaceuticals announces $15M private placement with potential $30M from warrant exercises
Upfront gross proceeds of $15M from sale of shares and pre-funded warrants at $0.5524 per unit.
Kiora licenses KIO-301 to Théa for up to $301M; $16M upfront, milestones, royalties
$16M upfront; up to $285M in milestones and tiered royalties up to low 20% on net sales.
Kiora Pharmaceuticals receives Nasdaq extension to July 15, 2024 for bid price compliance
Nasdaq grants additional 180-day compliance period until July 15, 2024 for $1.00 minimum bid price rule.
Kiora expands KIO-301 Phase 2 development after positive ABACUS-1 results; Q3 net loss $5.8M
ABACUS-1 Phase 1b showed KIO-301 safe, tolerable, with significant visual field improvements and increased brain activity on fMRI.
Kiora's KIO-301 shows vision improvement in blind RP patients in Phase I/II trial
Visual field increased significantly (p<0.05) at days 7 and 14; high-dose group gained 0.30 logMAR (3 lines) visual acuity.
Kiora Q2 net loss $2.6M; ABACUS phase 1b shows KIO-301 proof-of-concept in retinitis pigmentosa
Net loss $2.6M in Q2 2023 vs $2.4M Q2 2022; cash $8.0M at quarter end.
Kiora receives Nasdaq deficiency notice for stock below $1.00
Bid price closed below $1.00 for 30 consecutive business days as of July 18, 2023.
Amendment cancels up to $4.75M in near-term milestones Kiora owed Sentrx under 2018 license.
Kiora Pharmaceuticals closes $6.3M underwritten public offering, including full over-allotment
Gross proceeds of $6.3M from offering of common stock, Series F convertible preferred, and Class C/D warrants.
Net loss narrowed to $1.9M from $3.6M in Q1 2022; cash & equivalents $3.4M plus $1.7M R&D tax receivables.
Kiora's KIO-301 shows vision restoration in blind RP patients in Phase 1b
Preliminary Phase 1b ABACUS data: KIO-301 improved light perception in patients with no light perception.
Kiora Pharmaceuticals dismisses EisnerAmper, appoints Haskell & White as auditor
Dismissed EisnerAmper effective March 24, 2023 after competitive bid process.
Kiora Pharmaceuticals reports FY2022 net loss of $13.6M; clinical milestones on track for 2023
Net loss of $13.6M for FY2022, compared to $13.8M in FY2021; Q4 net loss $2.5M.
Kiora received IND approval from FDA for Phase 2 study of KIO-101 for ocular surface disease in autoimmune patients.
Issued 52,798 shares and 105,596 warrants at $3.788/share for $200K gross proceeds; warrants exercisable at $3.538.
Kiora raises $3.12M by reducing Class A warrant exercise price to $4.77, issuing new warrants
Gross proceeds of $3.12 million from immediate cash exercise of 654,609 Class A warrants.
On September 20, 2023 (the “Effective Date”), Paul Chaney resigned as Chairman and member of the Board of Directors (the “Board”) of Kiora Pharmaceuticals, Inc. (the “Company”) from the Audit Committee and Nominating and Corporate Governance Committee of the Board, effective as of the Effective Date.
the Board appointed Praveen Tyle, Ph.D. as Chairman of the Board.
On August 1, 2023, the Board of Directors (the “Board”) of Kiora Pharmaceuticals, Inc. (the “Company”) appointed Carmine Stengone as a member of the Board.
On September 13, 2022 (the “Effective Date”), Kiora Pharmaceuticals Inc. (the “Company”) appointed Melissa Tosca as Executive Vice President of Finance of the Company, effective as of the Effective Date.
Brian M. Strem, Ph.D., the Company’s President and Chief Executive Officer, will assume the role of the Company’s principal financial and accounting officer.
Effective as of June 16, 2022, Ms. Drexler resigned as Interim Chief Financial Officer of the Company
On April 21, 2022 (the “Effective Date”), the Board of Directors of Kiora Pharmaceuticals Inc. (the “Company”) appointed Susan L. Drexler as Interim Chief Financial Officer of the Company, effective as of the Effective Date.
Effective as of March 18, 2022, Brian M. Strem, Ph.D., the Company’s President and Chief Executive Officer, was appointed as the Company’s principal financial officer and principal accounting officer.
On March 18, 2022, Michael Meluzio resigned as the Corporate Controller of Kiora Pharmaceuticals, Inc. (the “Company”) to pursue other opportunities.
Sarah Romano resigned as Chief Financial Officer of the Company effective as of February 25, 2022
the Company appointed Michael Meluzio, CPA, the Corporate Controller of the Company, as the Company’s principal financial officer and principal accounting officer, effective as of the Effective Date.
On February 9, 2022, Sarah Romano, the Chief Financial Officer of Kiora Pharmaceuticals, Inc. (the “Company”), notified the Company that she will resign as Chief Financial Officer effective as of February 25, 2022 (the “Effective Date”) to pursue another opportunity.
Max materiality 0.85 · Median 0.62 · Most common event other_material